Alison Conlin is an Oncology physician affiliated with Providence Portland Medical Center. OpenAlex indexes 142 publications with 6,684 citations (h-index 28); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4805 NE Glisan St
Ste 6n50
Portland, OR 972132933
Telephone
503-215-5696Provider last certified this registry record 19 Feb 2021.
Clinical trials
- CAN1012 in Pre-Malignant DCIS and LCIS
Sponsor: Providence Health & Services
- Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Sponsor: Providence Health & Services
- Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.
Sponsor: Providence Health & Services
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20253 payments
- AstraZeneca Pharmaceuticals LPProgram year20256 payments
- Genentech USA, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
68%Aromatase Inhibitor55.4%Anastrozole62%Letrozole28%Exemestane10%Part D≥117 patientsKinase inhibitor9.1%Ibrance40%Verzenio23%Kisqali21%Everolimus16%Part D<11 patients+ 1 more class in this area
Nervous system
16.8%Gabapentinoids6%Gabapentin61%Pregabalin39%Part D<11 patientsPhenothiazine3.7%Prochlorperazine Maleate100%Part D≥19 patients+ 3 more classes in this area
Metabolism & gastrointestinal
6.2%Serotonin-3 Receptor Antagonist2.8%Ondansetron Odt61%Ondansetron Hcl39%Part D<11 patientsAntidiarrheal1.1%Diphenoxylate-Atropine100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2011–2013 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update
Journal of Clinical Oncology
2025 - Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
New England Journal of Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
John Heffner, MD
Providence Portland Medical Center
David Page, MD
Providence Portland Medical Center
Rom Leidner, MD
Providence Portland Medical Center
Herschel Wallen, MD
Providence Portland Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”